ArticleNature communications2026
Quantifying outer membrane permeability to β-lactam antibiotics using outer membrane vesicles that protect antibiotic-susceptible bacteria.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The development of innovative methods for quantitatively assessing drug efficacy is essential for advancing effective treatments against antibiotic-resistant bacteria. A key determinant of drug activity against resistant Gram-negative bacteria is the permeability of the bacterial cell envelope, particularly that of the outer membrane, which is the first line of defense against antimicrobials. In this study, we report a method to quantitatively evaluate outer membrane permeability to β-lactams (nitrocefin, mecillinam, cloxacillin) and to a β-lactamase inhibitor (avibactam) by monitoring their entry into outer membrane vesicles (OMVs) produced by Escherichia coli and Pseudomonas aeruginosa. We also show that drug-susceptible bacteria are effectively shielded from β-lactams by OMVs emanating from resistant bacteria that contain a periplasmic β-lactamase captured upon their formation. Altogether, our work provides a comprehensive framework for understanding how antimicrobial molecules interact with bacterial OMVs and how this process contributes to the spread of antibiotic resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.